<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532764</url>
  </required_header>
  <id_info>
    <org_study_id>PQ-010-001</org_study_id>
    <nct_id>NCT02532764</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients</brief_title>
  <official_title>Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProQR Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProQR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled study of single and multiple ascending doses
      of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and to determine the
      pharmacokinetics of QR-010 administered via inhalation in adult homozygous for ΔF508 Cystic
      Fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events from baseline through End of Study Visit</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events from baseline through End of Study</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicities (DLT) in each dose cohort from baseline through End of Study Visit.</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to end-of-treatment or presence of abnormalities regarding laboratory parameters, vital signs, ECG, spirometry, and physical findings.</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to end-of-treatment or presence of abnormalities regarding laboratory parameters using descriptive statistics, shift tables, and frequencies and percentage of subjects with treatment emergent abnormalities for each timepoint.</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to end-of-treatment or presence of abnormalities in vital signs will be summarized descriptively.</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to end-of-treatment or presence of abnormalities regarding ECG, spirometry, and physical findings will be summarized and listed as specified in the Statistical Analysis Plan.</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax)</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Serum Concentration (Tmax)</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (T1/2)</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve to final sample [AUC(0-last)]</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve to infinity [AUC(0-∞)]</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Clearance (CL)</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>8 weeks for Multiple-dose cohorts</time_frame>
    <description>Exploratory Efficacy</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in patient reported outcome measure CFQ-R Respiratory Symptom Score (CFQ-R RSS)</measure>
    <time_frame>8 weeks for Multiple-dose cohorts</time_frame>
    <description>Exploratory Efficacy</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in body weight</measure>
    <time_frame>8 weeks for Multiple-dose cohorts</time_frame>
    <description>Exploratory Efficacy</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Sweat chloride</measure>
    <time_frame>8 weeks for Multiple-dose cohorts</time_frame>
    <description>Exploratory Efficacy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>QR-010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QR-010</intervention_name>
    <description>Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
    <arm_group_label>QR-010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF as defined by iontophoretic pilocarpine sweat chloride test
             (sweat chloride) of &gt; 60 mmol/L

          -  Confirmation of CFTR gene mutations homozygous for the ΔF508 mutation

          -  Body mass index (BMI) ≥ 17 kg/m2

          -  Non-smoking for a minimum of two years

          -  FEV1 ≥70% of predicted normal for age, gender, and height, at Screening

          -  Stable lung function

          -  Adequate hepatic and renal function

        Exclusion Criteria:

          -  Breast‐feeding or pregnant

          -  Use of lumacaftor or ivacaftor

          -  Use of any investigational drug or device

          -  History of lung transplantation

          -  Hemoptysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Elborn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trust and Queen's University Belfast</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California USC - Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>940304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>01090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>03000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary (Health Sciences Centre)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Motol University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Center Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>02100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HGRL Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker- Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munich U. Hospital, Cystic Fibrosis Center for Adults</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>ΔF508</keyword>
  <keyword>RNA therapies</keyword>
  <keyword>antisense oligonucleotide</keyword>
  <keyword>CFTR</keyword>
  <keyword>F508del</keyword>
  <keyword>CF</keyword>
  <keyword>RNA therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

